𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cholinesterase inhibitors in dementia with Lewy bodies—a comparative analysis

✍ Scribed by Mani Bhasin; Elise Rowan; Keith Edwards; Ian McKeith

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
114 KB
Volume
22
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

To compare efficacy of different cholinesterase inhibitors (ChEIs) for treating patients with dementia with Lewy bodies (DLB).

Design

Retrospective comparison of three independent clinical studies of ChEI treatment using donepezil, galantamine or rivastigmine in patients with DLB.

Method

Data was obtained from open label trials of donepezil and galantamine and a placebo controlled randomized trial of rivastigmine in DLB. Changes in Mini Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI) and United Parkinson's Disease Rating Scale (UPDRS‐III) scores were compared between the three treatments at 12 and 20 weeks.

Results

All ChEIs significantly improved cognitive and neuropsychiatric measures. Reduction in the total NPI score appeared significantly greater after donepezil treatment. There was no significant increase in UPDRS‐III scores.

Conclusions

It is unclear to what extent these findings reflect true differences between ChEIs or are due to methodological artefacts of comparing different studies. There is so far no compelling evidence that any one ChEI is better than the other in treating DLB but head to head comparative studies of different ChEIs are warranted to clarify this. Copyright © 2007 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Cholinesterase inhibitors in advanced De
Cholinesterase inhibitors in advanced Dementia with Lewy bodies: increase or stop?
✍ Sanjeet Pakrasi; Alan Thomas; Urs P. Mosimann; David A. Cousins; Debbie Lett; Da 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB 👁 1 views

## Abstract ## Introduction There is little data on stopping cholinesterase inhibitors in Dementia with Lewy bodies (DLB). Equally, it is not known if increasing the dose of cholinesterase inhibitors may help neuropsychiatric symptoms in advanced DLB. ## Method We conducted an open label trial w

Olanzapine in dementia with Lewy bodies:
Olanzapine in dementia with Lewy bodies: a clinical study
✍ Zuzana Walker; Jan Grace; Ross Overshot; Sandya Satarasinghe; Alan Swan; Corneli 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 2 views

Objectives. Dementia with Lewy bodies (DLB) is now a well-recognized form of dementia in which psychosis and behavioural disturbance are common. Treatment with conventional neuroleptics is often very poorly tolerated. Olanzapine, a newly introduced atypical neuroleptic which binds to multiple recept

A comparative study of psychiatric sympt
A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia
✍ Dag Aarsland; Clive Ballard; Jan P. Larsen; Ian McKeith 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## Abstract ## Objectives To compare the frequency and clinical correlates of neuropsychiatric symptoms in patients with Parkinson's disease (PD) with and without dementia and in those with dementia with Lewy bodies (DLB). ## Methods Neuropsychiatric symptoms during the month prior to assessment

Economic evaluation of cholinesterase in
Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies
✍ Anders Gustavsson; Rohan Van Der Putt; Linus Jönsson; Rupert McShane 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 2 views

## Abstract ## Objective To assess the cost effectiveness of cholinesterase inhibitor (ChEI) treatment in patients with Alzheimer's disease (AD) and Dementia with Lewy bodies (DLB). ## Method We used 4‐month open label follow‐up data from routine memory clinic patients. There were 852 patients w

Extrapyramidal features in Parkinson's d
Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study
✍ David J. Burn; Elise N. Rowan; Thais Minett; Jonathon Sanders; Pat Myint; Jonath 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

## Abstract Risk factors predicting an increased risk of dementia in Parkinson's disease (PD) are not fully established. The dementia associated with PD (PDD) closely resembles dementia with Lewy bodies (DLB). Based upon a high frequency of non‐dopaminergic mediated clinical features in DLB, we pre

Visuospatial impairment in dementia with
Visuospatial impairment in dementia with Lewy bodies and Alzheimer's disease: a process analysis approach
✍ Martine Simard; Robert van Reekum; David Myran 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB 👁 2 views

## Abstract ## Background Reports of differential impairments on visual‐construction tasks in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) are sometimes controversial, whereas visual‐perceptual data are lacking. The existence of different clinical sub‐groups of DLB has been hypothe